PYNGF..$0.162 Pyng Medical Announces Release of E-MAT(TM) Emergency Medical Tourniquet-for the EMS Market
Dow Jones and Company, Inc. - Jun 10 at 09:01
Company Symbols: OTC-PINK:PYNGF, TorontoVE:PYT
VANCOUVER, BRITISH COLUMBIA--(Marketwire - June 10, 2011) - Pyng Medical Corp. (the "Company") (TSX VENTURE:PYT) announced today the release of their tourniquet marketed for the Emergency Medical Services (EMS) Market - E-MAT(TM).
"We are very excited to be launching this product for the EMS Market at a time when new tourniquet protocols are being introduced and implemented world-wide," commented Nadine Siqueland Gaston, Vice President of Global Sales and Marketing for Pyng.
The E-MAT(TM) features a bright, EMS orange color, setting it apart from its surroundings and making it noticeable at an accident scene. "This new high- visibility color will make it easy to see that a tourniquet has been placed on a patient," added Nadine. "It is also lightweight and compact, making it an easy fit into any medical bag."
With its new color, the E-MAT(TM) contains all the same award-winning features of the original MAT(R). By providing fast and easy application, even to trapped limbs, complete blood flow occlusion is achieved in under 30 seconds. "The E- MAT(TM) offers First Responders a quick and simple solution to stop severe extremity blood loss, allowing them time to asses other injuries," added Ms. Gaston.
About Pyng Medical Corp.
Pyng Medical Corp. commercializes award-winning trauma and resuscitation products for front-line critical care personnel. Pyng's expanded product portfolio includes a variety of innovative, lifesaving tools. With growing markets in North America, Europe and Asia, Pyng offers user-preferred medical devices for use by hospital staff, emergency medical services and military forces worldwide.
Safe Harbour Statement; Forward-Looking Statements: This release may contain forward-looking statements based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. Some of the forward-looking statements may be identified by words like "expects", "anticipates", "plans", "intends", " projects", "indicates", and similar expressions. These statements are not guarantees of future performance and involve a number of risks, uncertainties and assumptions. Many factors, including those discussed more fully elsewhere in this release and in documents which may be filed with the British Columbia Securities Commission, the Alberta Securities Commission, the Ontario Securities Commission, the TSX Venture Exchange, as well as other USA Commissions, could cause results to differ materially from those stated. These factors include, but are not limited to changes in the laws, regulations, policies and economic conditions, including inflation, interest and foreign currency exchange rates, of countries in which the Company does business; competitive pressures; successful integration of structural changes,including restructuring plans, acquisitions, divestitures and alliances; cost of raw material, research and development of new products, including regulatory approval and market acceptance; and seasonality of sales in some products.
Neither the TSX Venture Exchange nor its Regulatory Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
FOR FURTHER INFORMATION PLEASE CONTACT:
Pyng Medical Corp.
Nadine Gaston
VP of Global Sales and Marketing
206.226.3082
www.pyng.com
